Tedizolid phosphate
As of the edition of 20 October 2026, Tedizolid phosphate is a small molecule: marketed, first approved in 2014 (US); US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Sivextro
- First approved
- 20 June 2014 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Bayer; 2 holders in all
- Registered trials
- 28, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2030.
The last listed US drug-substance patent ends in 2030. The application that gives this date is held by Merck & Co..
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product12 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 12 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 19 | 19 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 6 | 6 | 0 | 0 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Originator and Lead sponsor of trials | 2008 to now |
| Bayer | Applicant and Lead sponsor of trials | 2013 to now |